BioXpress Therapeutics

BioXpress Therapeutics is a Switzerland-based company specializing in the development of high-quality monoclonal antibody (mAb) biosimilar therapeutics. The company focuses on creating biosimilars, which are highly similar versions of existing biologic drugs in terms of quality, safety and efficacy. BioXpress Therapeutics offers expertise in biosimilar development, including design consultancy, cell line development, and process development. The company aims to produce biologics that can positively impact patient lives by providing access to lower-cost biotherapeutic options.

BioXpress Therapeutics has established itself as a world-class developer in the biosimilars space. Its capabilities span from small-scale biosimilar development through to larger-scale manufacturing processes. The company leverages its scientific expertise, analytical know-how, and track record in delivering biosimilars to support third-party customers in bringing biosimilar products to market.

In July 2021, BioXpress Therapeutics entered into a strategic partnership with Abzena, a global contract research and manufacturing organization. This collaboration created an integrated solution for biosimilar drug developers, combining BioXpress Therapeutics' expertise in biosimilar development with Abzena's capabilities in GMP manufacturing. The partnership aims to provide a de-risked approach for bringing biosimilars from early development stages through clinical trials and commercial production.

Key customers and partnerships

BioXpress Therapeutics' key partnership is with Abzena, announced in July 2021. This collaboration allows the two companies to offer end-to-end services for biosimilar development and manufacturing to third-party customers globally. The integrated offering spans from initial design consultancy and cell line development to clinical and commercial GMP manufacturing.

The partnership with Abzena enables BioXpress Therapeutics to expand its services and provide a more comprehensive solution for biosimilar drug developers. By combining their complementary strengths, the two companies aim to simplify development timelines and offer a flexible, innovative approach to bringing biosimilars to market. This strategic alliance positions BioXpress Therapeutics to better serve pharmaceutical companies looking to enter the growing biosimilars market.